Galectin Therapeutics Inc.

GALT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001133416

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $19.5M
Warnings	thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 31, 2026 235 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026
Last close	$2.71 2026-11-20; market equity $273.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 9.8						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(37.6%)	(6.7%)		9.8	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 80.0						
Altman Z double-prime	(76.20)	0.31		93.8	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.42x	2.68x		66.2	781	2025-12-31
Growth and financing, sleeve percentile 50.7						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	(2.8%)	3.2%		58.3	663	2025-12-31
Net share issuance, one year	4.2%	1.6%		43.0	626	2026-03-02

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(33.2%)	(1.7%)	28
Distance from 52-week high	(58.7%)	(33.0%)	28
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(6.3%)	0.6%	32
Book value to price	(0.13)	0.29	6
Sales to price	not computable	0.38	
Composite equity issuance, five years	56.8%	13.5%	74
Relative strength against the sector, log excess return	(0.58)	(0.19)	28
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$11.7M
Operating cash flow, four quarters	-$14.6M
Months of runway	9.6
Days since last periodic filing	5 (10-Q received Nov 16, 2026)
Median daily dollar volume, 63 sessions	$754,760

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$30.8M	2025-12-31	2026-03-31	10-K	26-012155
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$23.9M	2025-12-31	2026-03-31	10-K	26-012155
3	assets	us-gaap:Assets	$19.5M	2025-12-31	2026-03-31	10-K	26-012155
4	assets	us-gaap:Assets	$17.5M	2024-12-31	2026-03-31	10-K	26-012155
5	current assets	us-gaap:AssetsCurrent	$19.4M	2025-12-31	2026-03-31	10-K	26-012155
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.0M	2025-12-31	2026-03-31	10-K	26-012155
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$432.5M	2025-12-31	2026-03-31	10-K	26-012155
8	operating income	us-gaap:OperatingIncomeLoss	-$20.1M	2025-12-31	2026-03-31	10-K	26-012155
9	book equity	us-gaap:StockholdersEquity	-$127.9M	2025-12-31	2026-03-31	10-K	26-012155
10	liabilities	us-gaap:Liabilities	$145.7M	2025-12-31	2026-03-31	10-K	26-012155
11	operating income	us-gaap:OperatingIncomeLoss	-$38.1M	2023-12-31	2025-03-31	10-K	25-011169
12	interest expense	us-gaap:InterestExpense	$2.8M	2023-12-31	2024-03-29	10-K	24-016452
13	assets	us-gaap:Assets	$28.2M	2023-12-31	2025-03-31	10-K	25-011169
14	assets	us-gaap:Assets	$21.3M	2022-12-31	2024-03-29	10-K	24-016452
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	65,827,448	2026-03-02	2026-03-31	10-K	26-012155
16	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,180,491	2025-03-03	2025-03-31	10-K	25-011169

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.